Boston Trust Walden Corp Decreases Stake in Johnson & Johnson $JNJ

Boston Trust Walden Corp reduced its position in Johnson & Johnson (NYSE:JNJ) by 7.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,014,444 shares of the company’s stock after selling 77,559 shares during the period. Johnson & Johnson accounts for about 1.1% of Boston Trust Walden Corp’s investment portfolio, making the stock its 11th biggest position. Boston Trust Walden Corp’s holdings in Johnson & Johnson were worth $154,956,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in JNJ. Nuveen LLC purchased a new stake in shares of Johnson & Johnson in the first quarter worth about $1,369,188,000. Bank of New York Mellon Corp raised its position in Johnson & Johnson by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after purchasing an additional 4,842,582 shares during the period. Pacer Advisors Inc. raised its position in Johnson & Johnson by 1,382.0% during the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock valued at $502,509,000 after purchasing an additional 2,825,626 shares during the period. Assenagon Asset Management S.A. raised its position in Johnson & Johnson by 159.6% during the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after purchasing an additional 2,557,388 shares during the period. Finally, Kingstone Capital Partners Texas LLC purchased a new stake in Johnson & Johnson during the second quarter valued at approximately $401,420,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent research reports. Stifel Nicolaus upped their price objective on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research report on Wednesday. Raymond James Financial upped their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research report on Wednesday. Cowen restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday. Weiss Ratings upgraded Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Finally, The Goldman Sachs Group upped their price objective on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $199.59.

Johnson & Johnson Trading Up 0.3%

Shares of NYSE JNJ opened at $191.79 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The business’s 50 day moving average price is $180.09 and its 200-day moving average price is $164.52. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.40. The company has a market cap of $461.90 billion, a price-to-earnings ratio of 18.51, a PEG ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.